Cancer Program

ChemoCentryx scientists have made a breakthrough discovery regarding the role of chemokines and chemokine receptors in the establishment of cancers and in the process of tumor angiogenesis. Through our research into the role of CXC chemokines and their corresponding receptors, we have discovered an "orphan" receptor whose expression is most commonly detected on tumor cells. Further research in our labs has demonstrated that this receptor is involved at an extremely fundamental level in vascular development, making it a promising anti-angiogenic target.

ChemoCentryx is currently conducting pre-clinical research on several chemokine receptors with anti-tumor potential. Our goal in these programs is to further elucidate the specific role of each chemokine receptor in a variety of cancers and to identify the best agent for development of an anti-tumorigenic oral medicine that could halt the progress of disease. In contrast to standard chemotherapeutic approaches, which can be very toxic, the ChemoCentryx compounds target the receptors associated with tumor growth with the aim of stopping cancer progression without causing detrimental effects such as generalized immunosuppression or cytotoxicity.

^ Return to Top